Molecular Cancer Research: 17 (2)

Highlights

Highlights

Highlights of This Issue

Mol Cancer Res February 1 2019 17 (2) 335-335;

Review

Review

Internalization of Exosomes through Receptor-Mediated Endocytosis

Amber Gonda, Janviere Kabagwira, Girish N. Senthil and Nathan R. Wall

Mol Cancer Res February 1 2019 17 (2) 337-347; DOI:10.1158/1541-7786.MCR-18-0891

Rapid Impact

Rapid Impact

Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer

Yuqing Zhang, Amanda Kirane, Huocong Huang, Noah B. Sorrelle, Francis J. Burrows, Michael T. Dellinger and Rolf A. Brekken

Mol Cancer Res February 1 2019 17 (2) 348-355; DOI:10.1158/1541-7786.MCR-18-0427

Cell Cycle and Senescence

Cell Cycle and Senescence | AuthorChoice

AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer

Haley D. Axelrod, Kenneth C. Valkenburg, Sarah R. Amend, Jessica L. Hicks, Princy Parsana, Gonzalo Torga, Angelo M. DeMarzo and Kenneth J. Pienta

Mol Cancer Res February 1 2019 17 (2) 356-369; DOI:10.1158/1541-7786.MCR-18-0718
Cell Cycle and Senescence

UNC-45A Is a Novel Microtubule-Associated Protein and Regulator of Paclitaxel Sensitivity in Ovarian Cancer Cells

Ashley Mooneyham, Yoshie Iizuka, Qing Yang, Courtney Coombes, Mark McClellan, Vijayalakshmi Shridhar, Edith Emmings, Mihir Shetty, Liqiang Chen, Teng Ai, Joyce Meints, Michael K. Lee, Melissa Gardner and Martina Bazzaro

Mol Cancer Res February 1 2019 17 (2) 370-383; DOI:10.1158/1541-7786.MCR-18-0670

Cell Death and Survival

Cell Death and Survival

Inhibiting Integrin β8 to Differentiate and Radiosensitize Glioblastoma-Initiating Cells

Laure Malric, Sylvie Monferran, Caroline Delmas, Florent Arnauduc, Perrine Dahan, Sabrina Boyrie, Pauline Deshors, Vincent Lubrano, Dina Ferreira Da Mota, Julia Gilhodes, Thomas Filleron, Aurore Siegfried, Solène Evrard, Aline Kowalski-Chauvel, Elizabeth Cohen-Jonathan Moyal, Christine Toulas and Anthony Lemarié

Mol Cancer Res February 1 2019 17 (2) 384-397; DOI:10.1158/1541-7786.MCR-18-0386
Cell Death and Survival | AuthorChoice

α_vβ₃ Integrin Mediates Radioresistance of Prostate Cancer Cells through Regulation of Survivin

Tao Wang, Jiayi Huang, Mai Vue, Michael R. Alavian, Hira Lal Goel, Dario C. Altieri, Lucia R. Languino and Thomas J. FitzGerald

Mol Cancer Res February 1 2019 17 (2) 398-408; DOI:10.1158/1541-7786.MCR-18-0544
Cell Death and Survival | AuthorChoice

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

Todd A. Hopkins, William B. Ainsworth, Paul A. Ellis, Cherrie K. Donawho, Enrico L. DiGiammarino, Sanjay C. Panchal, Vivek C. Abraham, Mikkel A. Algire, Yan Shi, Amanda M. Olson, Eric F. Johnson, Julie L. Wilsbacher and David Maag

Mol Cancer Res February 1 2019 17 (2) 409-419; DOI:10.1158/1541-7786.MCR-18-0138
Cell Death and Survival

Loss of Fas Expression and Function Is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Wei Xiao, Mohammed L. Ibrahim, Priscilla S. Redd, John D. Klement, Chunwan Lu, Dafeng Yang, Natasha M. Savage and Kebin Liu

Mol Cancer Res February 1 2019 17 (2) 420-430; DOI:10.1158/1541-7786.MCR-18-0455

DNA Damage and Repair

DNA Damage and Repair | AuthorChoice

PARP Inhibition Induces Enrichment of DNA Repair–Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells

Chiara Bellio, Celeste DiGloria, Rosemary Foster, Kaitlyn James, Panagiotis A. Konstantinopoulos, Whitfield B. Growdon and Bo R. Rueda

Mol Cancer Res February 1 2019 17 (2) 431-445; DOI:10.1158/1541-7786.MCR-18-0594

Genomics

Genomics | AuthorChoice

Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate

Habiba Elfandy, Joshua Armenia, Filippo Pederzoli, Eli Pullman, Nelma Pertega-Gomes, Nikolaus Schultz, Kartik Viswanathan, Aram Vosoughi, Mirjam Blattner, Konrad H. Stopsack, Giorgia Zadra, Kathryn L. Penney, Juan Miguel Mosquera, Svitlana Tyekucheva, Lorelei A. Mucci, Christopher Barbieri and Massimo Loda

Mol Cancer Res February 1 2019 17 (2) 446-456; DOI:10.1158/1541-7786.MCR-18-0440
Genomics

Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer

Ahmed Basudan, Nolan Priedigkeit, Ryan J. Hartmaier, Ethan S. Sokol, Amir Bahreini, Rebecca J. Watters, Michelle M. Boisen, Rohit Bhargava, Kurt R. Weiss, Maria M. Karsten, Carsten Denkert, Jens-Uwe Blohmer, Jose P. Leone, Ronald L. Hamilton, Adam M. Brufsky, Esther Elishaev, Peter C. Lucas, Adrian V. Lee and Steffi Oesterreich

Mol Cancer Res February 1 2019 17 (2) 457-468; DOI:10.1158/1541-7786.MCR-18-0946
Genomics

High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer

Simon Garinet, Géraldine Pignot, Sophie Vacher, Constance Le Goux, Anne Schnitzler, Walid Chemlali, Nanor Sirab, Nicolas Barry Delongchamps, Marc Zerbib, Mathilde Sibony, Yves Allory, Diane Damotte and Ivan Bieche

Mol Cancer Res February 1 2019 17 (2) 469-475; DOI:10.1158/1541-7786.MCR-18-0363
Genomics

Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas

Fengju Chen, Yiqun Zhang, Sooryanarayana Varambally and Chad J. Creighton

Mol Cancer Res February 1 2019 17 (2) 476-487; DOI:10.1158/1541-7786.MCR-18-0601
Genomics

Mitochondrial DNA Mutations are Associated with Ulcerative Colitis Preneoplasia but Tend to be Negatively Selected in Cancer

Kathryn T. Baker, Daniela Nachmanson, Shilpa Kumar, Mary J. Emond, Cigdem Ussakli, Teresa A. Brentnall, Scott R. Kennedy and Rosa Ana Risques

Mol Cancer Res February 1 2019 17 (2) 488-498; DOI:10.1158/1541-7786.MCR-18-0520
Genomics

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells

Kei Namba, Kazuhiko Shien, Yuta Takahashi, Hidejiro Torigoe, Hiroki Sato, Takahiro Yoshioka, Tatsuaki Takeda, Eisuke Kurihara, Yusuke Ogoshi, Hiromasa Yamamoto, Junichi Soh, Shuta Tomida and Shinichi Toyooka

Mol Cancer Res February 1 2019 17 (2) 499-507; DOI:10.1158/1541-7786.MCR-18-0628

Oncogenes and Tumor Suppressors

Oncogenes and Tumor Suppressors

RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer

Mahsa Zarei, Shruti Lal, Ali Vaziri-Gohar, Kevin O'Hayer, Venugopal Gunda, Pankaj K. Singh, Jonathan R. Brody and Jordan M. Winter

Mol Cancer Res February 1 2019 17 (2) 508-520; DOI:10.1158/1541-7786.MCR-18-0557
Oncogenes and Tumor Suppressors

Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/β-Catenin Signaling

Wenhui Wang, Shan Li, Pengyu Liu, Kostandinos Sideras, Harmen J.G. van de Werken, Marieke van der Heide, Wanlu Cao, Marla Lavrijsen, Maikel P. Peppelenbosch, Marco Bruno, Qiuwei Pan and Ron Smits

Mol Cancer Res February 1 2019 17 (2) 521-531; DOI:10.1158/1541-7786.MCR-18-0054
Oncogenes and Tumor Suppressors

The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT

Molly R. Ryan, Christal D. Sohl, BeiBei Luo and Karen S. Anderson

Mol Cancer Res February 1 2019 17 (2) 532-543; DOI:10.1158/1541-7786.MCR-18-0429
Oncogenes and Tumor Suppressors

c-MYC Drives Breast Cancer Metastasis to the Brain, but Promotes Synthetic Lethality with TRAIL

Ho Yeon Lee, Junghwa Cha, Seon Kyu Kim, Jun Hyung Park, Ki Hoon Song, Pilnam Kim and Mi-Young Kim

Mol Cancer Res February 1 2019 17 (2) 544-554; DOI:10.1158/1541-7786.MCR-18-0630
Oncogenes and Tumor Suppressors

DNA Damage, Liver Injury, and Tumorigenesis: Consequences of DDX3X Loss

Chieh-Hsiang Chan, Chun-Ming Chen, Yan-Hwa Wu Lee and Li-Ru You

Mol Cancer Res February 1 2019 17 (2) 555-566; DOI:10.1158/1541-7786.MCR-18-0551
Oncogenes and Tumor Suppressors

Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-cell Lymphoma

Eric P. Rahrmann, Natalie K. Wolf, George M. Otto, Lynn Heltemes-Harris, Laura B. Ramsey, Jingmin Shu, Rebecca S. LaRue, Michael A. Linden, Susan K. Rathe, Timothy K. Starr, Michael A. Farrar, Branden S. Moriarity and David A. Largaespada

Mol Cancer Res February 1 2019 17 (2) 567-582; DOI:10.1158/1541-7786.MCR-18-0582
Oncogenes and Tumor Suppressors

PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas

Kristen S. Hill, Evan R. Roberts, Xue Wang, Ellen Marin, Taeeun D. Park, Sorany Son, Yuan Ren, Bin Fang, Sean Yoder, Sungjune Kim, Lixin Wan, Amod A. Sarnaik, John M. Koomen, Jane L. Messina, Jamie K. Teer, Youngchul Kim, Jie Wu, Charles E. Chalfant and Minjung Kim

Mol Cancer Res February 1 2019 17 (2) 583-593; DOI:10.1158/1541-7786.MCR-18-0777
Oncogenes and Tumor Suppressors | AuthorChoice

Modulation of Mutant Kras^G12D-Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function

Xiaorong Zhou, Mahesh S. Padanad, Bret M. Evers, Bethany Smith, Nicole Novaresi, Shruthy Suresh, James A. Richardson, Emily Stein, Jingfei Zhu, Robert E. Hammer and Kathryn A. O'Donnell

Mol Cancer Res February 1 2019 17 (2) 594-603; DOI:10.1158/1541-7786.MCR-18-0739
Oncogenes and Tumor Suppressors

CCR2 Chemokine Receptors Enhance Growth and Cell-Cycle Progression of Breast Cancer Cells through SRC and PKC Activation

Min Yao, Wei Fang, Curtis Smart, Qingting Hu, Shixia Huang, Nehemiah Alvarez, Patrick Fields and Nikki Cheng

Mol Cancer Res February 1 2019 17 (2) 604-617; DOI:10.1158/1541-7786.MCR-18-0750
Oncogenes and Tumor Suppressors

PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance

Kenji Zennami, Su Mi Choi, Ross Liao, Ying Li, Wikum Dinalankara, Luigi Marchionni, Fatema H. Rafiqi, Akira Kurozumi, Koji Hatano and Shawn E. Lupold

Mol Cancer Res February 1 2019 17 (2) 618-627; DOI:10.1158/1541-7786.MCR-18-0837

Signal Transduction

Signal Transduction | AuthorChoice

Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1–EGFR Signaling in a Xenograft Model of CD44⁺/CD24^low/CD90⁺ Myoepithelial Cells

Micaela Montanari, Maria Rita Carbone, Luigi Coppola, Mario Giuliano, Grazia Arpino, Rossella Lauria, Agostina Nardone, Felicia Leccia, Meghana V. Trivedi, Corrado Garbi, Roberto Bianco, Enrico V. Avvedimento, Sabino De Placido and Bianca Maria Veneziani

Mol Cancer Res February 1 2019 17 (2) 628-641; DOI:10.1158/1541-7786.MCR-17-0324
Signal Transduction

Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance

Ida Aronchik, Yumin Dai, Matt Labenski, Carmen Barnes, Terri Jones, Lixin Qiao, Lisa Beebe, Mehnaz Malek, Winfried Elis, Tao Shi, Konstantinos Mavrommatis, Gordon L. Bray and Ellen H. Filvaroff

Mol Cancer Res February 1 2019 17 (2) 642-654; DOI:10.1158/1541-7786.MCR-17-0554
Signal Transduction

Nuclear E-Cadherin Acetylation Promotes Colorectal Tumorigenesis via Enhancing β-Catenin Activity

Yongxu Zhao, Tao Yu, Nan Zhang, Jianxia Chen, Peng Zhang, Shuang Li, Lijun Luo, Zhenling Cui, Yue Qin and Feng Liu

Mol Cancer Res February 1 2019 17 (2) 655-665; DOI:10.1158/1541-7786.MCR-18-0637

Main menu

User menu

Search

Table of Contents

Highlights

Review

Rapid Impact

Cell Cycle and Senescence

Cell Death and Survival

DNA Damage and Repair

Genomics

Oncogenes and Tumor Suppressors

Signal Transduction

Issue Highlights

Jump to

Articles

Information for

About MCR